Prostate Cancer – Global Drug Forecast and Market Analysis to 2028

The prostate cancer market in the 8 major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China) is expected to experience a moderate growth between 2018 and 2018. The main drivers of growth will be an aging population, continued uptake of second-generation hormonal agents in the metastatic hormone naïve (mHNPC) and non-metastatic castration resistant (nmCRPC) prostate cancer settings, and the launch and uptake of 13 new premium-priced therapies, including the newly approved Nubeqa (darolutamide).

Until recently, the hormone sensitive setting has been dominated by the use of cheaper first-generation hormonal agents, with the use of premium-priced second-generation hormonal agents (Xtandi and Zytiga) limited to metastatic CRPC. The prostate cancer competitive landscape is experiencing a substantial change. Given that Zytiga and Xtandi are limited by the insurgence of acquired resistance, physicians will face the critical issue of determining the best treatment sequence for subsequent lines of therapy, most notably in the mCRPC setting. Additionally, companies are now moving toward a more personalized approach in prostate cancer, targeting mCRPC patients with specific genetic signatures, such as PTEN loss and DNA repair abnormalities. GlobalData expects these biomarker-driven drug development strategies to induce further patient stratification and to add complexity to the CRPC treatment algorithm.

Scope

Overview of prostate cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.

Annualized prostate cancer therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in seven patient segments, forecast from 2018 to 2028.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the prostate cancer therapeutics market.

Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for prostate cancer. The most promising candidates in Phase III development are profiled.

Analysis of the current and future market competition in the global prostate cancer market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

The main driver of the growth of the prostate cancer market will be the continued uptake of second-generation hormonal agents into mHNPC and nmCRPC, where the extended treatment duration will drive overall sales. The second strongest driver will be the increasing number of incident cases.

To gain approval and obtain reimbursement, it is essential for pipeline drugs to demonstrate greater efficacy (overall survival) compared with available agents. For this reason, agents positioned as first-line mCRPC treatments are being investigated in combination with second-generation hormonal agents, the current standard of care (SOC), to limit the “standard-of-care hurdle“. The earlier use of these agents in the hormone-sensitive disease may negatively affect the uptake of this combination in the later line of treatment, mCRPC.

Due to concerns related to the high annual cost of therapy, GlobalData expects heavy generic erosion of Zytiga when abiraterone generics launch, starting in 2018.

Reasons to Buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global prostate cancer market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global prostate cancer market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.